The advanced methods of hyperhidrosis treatment using Botulinum toxin
DOI:
https://doi.org/10.12775/JEHS.2022.12.09.104Keywords
hyperhidrosis, botulinum toxin, sweat glandAbstract
Introduction and purpose: Sweating plays an important role in the mechanism of human thermoregulation. A state in which the amount of sweat produced exceeds the physiological demand is called hyperhidrosis. About 4.8% of the population complains of this condition. The inconvenience of excessive sweat production significantly decrease the standard of living of patients suffering from this disorder. Nowadays, botulinum toxin injections are increasingly being used as a therapy for excessive sweating.
Brief description of the state of knowledge: Botulinum toxin is an exotoxin produced by the bacteria Clostridium botulinum . It is now considered one of the most potent poisons found in nature. Thanks to research conducted since the 1970s, the positive effects of using TB to treat strabismus, eyelid spasm, torticollis and other conditions associated with excessive muscle spasticity have been noted. This discovery coused a flood of subsequent research on the use of botulinum toxin in medicine and cosmetology. It derives its features from inhibiting the release of Acetylcholine in nerve endings, which prevents muscle contraction. Acetylcholine is the main transmitter of the sympathetic nervous system, which innervates the sweat glands. Thanks to these features, botulinum toxin has begun to be widely used to treat excessive sweating.
Summary: Excessive sweating is very often resistant to treatment attempts with iontophoresis or external substances. Botulinum toxin injections into the areas most affected by the condition, which are most often the hands, feet, armpits, bring significant improvement in patients. Currently, research is being conducted about the use of botulinum toxin in other areas of the body.
References
Erbguth, F. From poison to remedy: The chequered history of botulinum toxin. J. Neural Transm. 2008, 115, 559–565.
M. Drożdżyńska, I. Sobieraj-Garbiak, A. Chlasta, M. Jastrzębska, Toksyna botulinowa i jej zastosowanie w medycynie [Botulinum toxin and ints usage in medicine] Journal of Laboratory Diagnostics Diagn Lab 2015; 51(2):139-146. Polish
Solish N, Bertucci V, Dansereau A, et al. A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee. Dermatol Surg. 2007;33:908-923.
Sato K, Kang WH, Saga K, Sato KT. Biology of sweat glands and their disorders. I. Normal sweat gland function. J Am Acad Dermatol. 1989;20:537-563.
Shargall Y, Spratt E, Zeldin RA. Hyperhidrosis: what is it and why does it occur? Thorac Surg Clin. 2008;18:125-132.
Cohen JL, Cohen G, Solish N, Murray CA. Diagnosis, impact, and management of focal hyperhidrosis: treatment review including botulinum toxin therapy. Facial Plast Surg Clin North Am. 2007;15:17-30.
Schick CH. Pathophysiology of hyperhidrosis. Thorac Surg Clin. 2016;26:389-393.
Lakraj AAD, Moghimi N, Jabbari B. Hyperhidrosis: anatomy, pathophysiology and treatment with emphasis on the role of botulinum toxins. Toxins. 2013;5:821-840.
Atkins JL, Butler PE. Hyperhidrosis: a review of current management. Plast Reconstr Surg. 2002;110:222-228.
Lonsdale-Eccles A, Leonard N, Lawrence C. Axillary hyperhidrosis: eccrine or apocrine? Clin Exp Dermatol. 2003;28:2-7.
S. Nawrocki, J. Cha The etiology, diagnosis, and managment of hyperhydrosis: A compehensive review: Etiology and clinical work-up. J Am Acad Dermatol. 2019 Sep;81(3):657-666.
Hexsel D, Camozzato FO. Hyperhidrosis. In: Dermatology in Public Health Environments. Springer; 2018:1379-1393.
Strutton DR, Kowalski JW, Glaser DA, Stang PE. US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey. J Am Acad Dermatol. 2004;51:241-248.
Leung AKC, Chan PYH, Choi MCK. Hyperhidrosis. Int J Dermatol. 1999;38:561-567.
Walling HW. Primary hyperhidrosis increases the risk of cutaneous infection: a case-control study of 387 patients. J Am Acad Dermatol. 2009;61:242-246.
Campanati A, Penna L, Guzzo T, et al. A quality-of-life assessment in patients with hyperhidrosis before and after treatment with botulinum toxin: results of an open-label study. Clin Ther. 2003;25:298-308.
Cina CS, Clase CM. The Illness Intrusiveness Rating Scale: a measure of severity in individuals with hyperhidrosis. Qual Life Res. 1999;8:693-698.
Naumann MK, Hamm H, Lowe NJ. Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial. Br J Dermatol. 2002;147:1218-1226.
Bushara KO, Park DM, Jones JC, et al: Botulinum toxin – a possible new treatment for axillary hyperhidrosis. Clin Exp Derm 1996;21:276–278.
Blaheta JH, Vollert B, Zuder D, et al: Intravenous regional anesthesia (Bier’s block) for botulinum toxin therapy of palmar hyperhidrosis is safe and effective. Dermatol Surg 2002;28:666–672.
Hayton M, Stanley JK, Lowe NJ: A review of peripheral nerve blockade as local anaesthesia in the treatment of palmer hyperhidrosis. Br J Dermatol 2003;149:447–451.
Doft M.A., Hardy K.L., Aschermann J.A., Treatment of hyperhidrosis with botulinum toxin, Aesthet Surg J 2012 Feb;32(2):238-44.
Tomoko Fujimoto. Pathopysiology and treatment of hyperhidrosis. Curr Probl Dermatol. 2016;51:86-93.
Solish N, Bertucci V, Dansereau A, et al: A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee. Dermatol Surg 2007;33:908–923.
Glaser D.A., Galperin T.A., Botulinum Toxin for hyperhidrosis of area other than the axillae and palms/soles. Dermatol Clin. 2014 Oct;32(4):517-25.
Naumann M, Lowe NJ, Kumar CR, et al. Botulinum toxin type A is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study. Arch Dermatol 2003;139:731-736.
Boni R, Kreyden OP, Burg G. Revival of the use of botulinum toxin: application in dermatology. Dermatology 2000;200:287-291.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Agnieszka Blicharz, Magdalena Marzęda, Tomasz Swatko, Tomasz Stachura, Natalia Rybak
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 535
Number of citations: 0